Palvella Therapeutics
Wayne, United States (US) · Science and Engineering
Do your work at Palvella Therapeutics?
Claim this profile to manage your company.
Verified by Enterprise League
Data quality
Complete · Accuracy
Last verified
Jun 2026
Overview
Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.
Contact Details
info@palvellatx.com
Wayne, United States (US)
Founded
2015
Employees
20-30
Categories
Keywords
#Biotechnology
#Rare Diseases
#Genetic Skin Conditions
#lymphatic malformations
Companies teams usually look at after Palvella Therapeutics
Comparing a few options usually leads to better decisions
Save companies to compare later. Useful when sharing options with your team
This is how your company profile looks to others.